NOVOB80:BKK
Novo
1,29 THB
arrow_downward
−0,77%(−0,0100) 1 D.
10-14, 23:33:34 GMT+7 · THB
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „NOVOB80“ įžvalgos...
Atidaryti
1,31 THB
Aukšta
1,31 THB
Žema
1,28 THB
Rinkos kapitalizacija
130,21 mlrd.
Vid. kiekis
3,93 mln.
Apimtis
2,76 mln.
52 sav. aukšta
2,02 THB
52 sav. žema
1,12 THB
Neapmokėtos akcijos
3,00 mlrd.
Darbuotojų skaičius
67 tūkst.
Atidaryti
1,31 THB
Aukšta
1,31 THB
Žema
1,28 THB
Rinkos kapitalizacija
130,21 mlrd.
Vid. kiekis
3,93 mln.
Apimtis
2,76 mln.
52 sav. aukšta
2,02 THB
52 sav. žema
1,12 THB
Neapmokėtos akcijos
3,00 mlrd.
Darbuotojų skaičius
67 tūkst.
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
Yahoo Finance
·
prieš 37 minutes
Is Novo Nordisk (NYSE:NVO) A Long Term Value Opportunity Now?
The Motley Fool
·
prieš 18 valandų
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
TipRanks
·
prieš 1 dieną
Novo Nordisk Details Progress in DKK 15 Billion Share Buyback Programme
Yahoo Finance
·
prieš 2 dienas
Novo Down 11% in a Month: How Should Investors Approach the Stock Now?
Profilis
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. Wikipedia
Apie „Novo“
Generalinis direktoriusMaziar Mike Doustdar
Darbuotojai66,7 tūkst.
Įkurta1923
Pagrindinė būstinėBagsværd, Sostinės regionas, Danija
Sektorius-
Svetainėnovonordisk.com